ArticleEndocrine oncology (Bristol, England)2026
SDHB and CDK1 protein expression in metastatic pheochromocytoma and paraganglioma.
Article in Endocrine oncology (Bristol, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pheochromocytomas and paragangliomas (PPGLs) are rare and mostly non-metastatic tumors originating from adrenal medulla and paraganglia. Metastatic PGLs have a worse prognosis, but currently, there are no established criteria to determine PPGL metastatic potential. Aim: The aim of this study was to investigate whether SDHB and CDK1 expression is associated with metastatic capacity in PPGL. Material and methods: A tissue microarray (TMA) was constructed from 175 tumors from a total of 149 unique PPGL patients treated at Sahlgrenska University Hospital. SDHB, CDK1, and proliferation index Ki-67 were assessed and correlated to metastatic capacity defined as a confirmed metastatic event. Results: Negative SDHB expression was more common in patients with metastatic PPGL and displayed a trend toward lower overall survival and correlation with higher Ki-67%. High CDK1 expression was not associated with any of the parameters mentioned above. Conclusion: Negative SDHB expression but not high CDK1 expression is associated with metastatic capacity in PPGL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.